CD4 and COVID-19: This correlation was stronger when analyzing the subgroup of moderate/severe patients (R = −0.596, P = 0.0091) (Figure 4C), suggesting that in vivo complement activation might be implicated in CD4 lymphopenia observed during acute COVID-19.